Working… Menu

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02229253
Recruitment Status : Completed
First Posted : September 1, 2014
Last Update Posted : November 27, 2017
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Brief Summary:
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Condition or disease Intervention/treatment
Advanced Hormone Sensitive Prostate Cancer Drug: degarelix

Layout table for study information
Study Type : Observational
Actual Enrollment : 112 participants
Observational Model: Cohort
Time Perspective: Prospective
Actual Study Start Date : September 2014
Actual Primary Completion Date : October 4, 2017
Actual Study Completion Date : October 4, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Degarelix

Group/Cohort Intervention/treatment
Treatment according to standard clinical practice.
Drug: degarelix
Other Name: Firmagon®

Primary Outcome Measures :
  1. Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice [ Time Frame: Up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients will be selected from prostate cancer patients in a hospital setting, meeting the inclusion criteria.

Inclusion Criteria:

  • Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion Criteria:

  • Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
  • Planned intermittent or short-term (< 12 months) degarelix treatment
  • Planned addition of, or switch to another form of androgen deprivation therapy during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02229253

Layout table for location information
Groene Hart Ziekenhuis (there may be other sites in this country)
Gouda, Netherlands
Sponsors and Collaborators
Ferring Pharmaceuticals
Layout table for investigator information
Study Director: Clinical Development Support Ferring Pharmaceuticals

Layout table for additonal information
Responsible Party: Ferring Pharmaceuticals Identifier: NCT02229253     History of Changes
Other Study ID Numbers: 000171
First Posted: September 1, 2014    Key Record Dates
Last Update Posted: November 27, 2017
Last Verified: November 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases